Search results for "Randomized Controlled Trial"

showing 10 items of 2199 documents

Advice for health-care professionals on how to retrieve more efficiently scientifically strong and up-to-date studies on treatments by PubMed.

2008

AND trial (Title/Abstract))). Obviously, clini- cians using the PubMed Clinical Queries may be unaware of the PubMed search engine technical approach even whether they can remain unaware of what the PubMed search engine is doing. We demonstrated substantial mild retrieval bias of PubMed Clinical Queries filter focusing on therapy (narrow search) that can miss up-to-date scientifically information on treatments. This bias occurs because the search string does not consider the Britannic English variant of the term randomized (i.e., randomised). We suggested a slight change in the original search string by the addition of the term randomised as follows: (randomized controlled trial (Publicatio…

PubMedEvidence-Based Medicinebusiness.industryHealth PersonnelAccess to Information MEDLINEInformation Storage and RetrievalSlight changemedicine.diseaseDatabases BibliographicAdvice (programming)law.inventionAccess to InformationRandomized controlled trialHealth OccupationslawHealth careEmergency MedicineInternal MedicineHumansMedicineMedical emergencybusiness
researchProduct

Disclosure of duplicative studies: damned if you don't

2012

Duplicative publication requires duplicative editorializing. There are many forms of lesser redundancy such as unacknowledged secondary analyses of randomized clinical trials, fragmentation of studies with concurrent submission to various journals, and serial updating of observational studies. These practices result in publication bias. We have revised our instructions to authors to include disclosure of similar articles that are published, in press, or submitted to other journals to the editors upon submission.

PublishingClinical Trials as TopicActuarial scienceComputer scienceWritingManuscripts Medical as TopicObstetrics and GynecologyDisclosurePublication biaslaw.inventionReproductive MedicineRandomized controlled triallawGermanyRedundancy (engineering)Observational studyGuideline AdherencePeriodicals as TopicEditorial PoliciesFertility and Sterility
researchProduct

New evidence in one-lung ventilation

2017

Mechanical ventilation in thoracic surgery has undergone significant changes in recent years due to the implementation of the protective ventilation. This review will analyze recent ventilatory strategies in one-lung ventilation. A MEDLINE research was performed using Mesh term "One-Lung Ventilation" including randomized clinical trials, metanalysis, reviews and systematic reviews published in the last 6 years. Search was performed on 21st March 2017. A total of 75 articles were initially found. After title and abstract review 14 articles were included. Protective ventilation is not simply synonymous of low tidal volume ventilation, but it also includes routine use of PEEP and alveolar recr…

Pulmonary Atelectasismedicine.medical_specialtySwinemedicine.medical_treatmentMEDLINElaw.inventionHypercapniaPositive-Pressure Respiration03 medical and health sciences0302 clinical medicineMeta-Analysis as TopicRandomized controlled trial030202 anesthesiologylawTidal VolumeAnimalsHumansMedicine030212 general & internal medicineExpirationIntensive care medicineRandomized Controlled Trials as TopicMechanical ventilationbusiness.industryGeneral Medicinerespiratory systemOne lung ventilationOne-Lung Ventilationrespiratory tract diseasesSystematic reviewCardiothoracic surgeryModels AnimalVentilation (architecture)Anesthesia Inhalationbusiness
researchProduct

Sigh in Patients With Acute Hypoxemic Respiratory Failure and ARDS

2021

Background Sigh is a cyclic brief recruitment maneuver: previous physiologic studies showed that its use could be an interesting addition to pressure support ventilation to improve lung elastance, decrease regional heterogeneity, and increase release of surfactant. Research Question Is the clinical application of sigh during pressure support ventilation (PSV) feasible? Study Design and Methods We conducted a multicenter noninferiority randomized clinical trial on adult intubated patients with acute hypoxemic respiratory failure or ARDS undergoing PSV. Patients were randomized to the no-sigh group and treated by PSV alone, or to the sigh group, treated by PSV plus sigh (increase in airway pr…

Pulmonary and Respiratory MedicineARDSbusiness.industryPressure support ventilationCritical Care and Intensive Care Medicinemedicine.diseaseSpontaneous breathing triallaw.invention03 medical and health sciences0302 clinical medicine030228 respiratory systemRandomized controlled triallawAnesthesiaBreathingMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessRespiratory minute volumePositive end-expiratory pressureTidal volumeChest
researchProduct

Hypersensitivity pneumonitis : Lessons from a randomized controlled trial in children

2021

Introduction Hypersensitivity pneumonitis (HP) in children is a severe interstitial lung disease and potentially, a chronic condition, if not treated appropriately. No evidence-based guidelines are available; in particular, the role of systemic glucocorticoid therapy is unclear. Methods The aim of this randomized, double-blind, placebo-controlled, parallel-group, multi-center, phase II trial in pediatric HP was to assess the outcome of HP in children after 6 months of treatment and to compare 3 months of treatment with oral prednisolone or placebo. Results After 1.5 years and the inclusion of only four children, we terminated the study prematurely. Two of the children randomized to predniso…

Pulmonary and Respiratory MedicineAdultChronic conditionPediatricsmedicine.medical_specialtyPrednisoloneMedizinPlacebolaw.inventionFEV1/FVC ratioRandomized controlled trialDouble-Blind MethodlawMedicineHumansChildGlucocorticoidsbusiness.industryInterstitial lung diseasemedicine.diseaseClinical trialPediatrics Perinatology and Child HealthPrednisolonebusinessLung Diseases InterstitialHypersensitivity pneumonitismedicine.drugAlveolitis Extrinsic Allergic
researchProduct

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

2020

Background There is no proven specific pharmacological treatment for patients with the acute respiratory distress syndrome (ARDS). The efficacy of corticosteroids in ARDS remains controversial. We aimed to assess the effects of dexamethasone in ARDS, which might change pulmonary and systemic inflammation and result in a decrease in duration of mechanical ventilation and mortality. Methods We did a multicentre, randomised controlled trial in a network of 17 intensive care units (ICUs) in teaching hospitals across Spain in patients with established moderate-to-severe ARDS (defined by a ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen of 200 mm Hg or less assesse…

Pulmonary and Respiratory MedicineAdultMaleARDSmedicine.medical_treatmentSeverity of Illness IndexDexamethasonelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawFraction of inspired oxygenIntensive careSeverity of illnessmedicineData monitoring committeeHumans030212 general & internal medicineGlucocorticoidsDexamethasoneAgedMechanical ventilationRespiratory Distress Syndromebusiness.industryMiddle Agedmedicine.diseaseRespiration ArtificialIntensive Care UnitsTreatment Outcome030228 respiratory systemAnesthesiaAdministration IntravenousFemalebusinessmedicine.drug
researchProduct

Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review.

2013

Hereditary angioedema (HAE) due to C1 esterase inhibitor (HAE-C1-INH) deficiency is a rare genetic disorder presenting with recurrent episodes of skin swellings, abdominal pain attacks, and potentially fatal laryngeal edema. This study was designed to review the efficacy and safety of pasteurized, human, plasma-derived C1-INH concentrate for the treatment of patients with HAE-C1-INH. A systematic search of electronic databases up to December 2011 was performed without language or date restrictions. Two reviewers completed the study selection using predefined inclusion criteria, tabulated, and analyzed the data. The data were inappropriate for meta-analysis; thus, a qualitative synthesis was…

Pulmonary and Respiratory MedicineAdultMaleAbdominal painmedicine.medical_specialtyAdolescentPlacebolaw.inventionYoung AdultQuality of lifeRandomized controlled triallawInternal medicineImmunology and AllergyMedicineHumansYoung adultChildRandomized Controlled Trials as TopicHereditary Angioedema Types I and IIbusiness.industryGeneral Medicinebacterial infections and mycosesmedicine.diseaseSystematic reviewTreatment OutcomeChild PreschoolHereditary angioedemaObservational studyFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinAllergy and asthma proceedings
researchProduct

Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignif…

2017

Chronic non-specific respiratory symptoms are difficult to manage. This trial aimed to evaluate the association between baseline fractional exhaled nitric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific respiratory symptoms.In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patients, aged 18-80 years, with cough, wheeze, or dyspnoea and less than 20% bronchodilator reversibility across 26 primary care centres and hospitals in the UK and Singapore. Patients were assessed for 2 weeks before being randomly assigned (1:1) to 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 μg, two puffs twice per day, equi…

Pulmonary and Respiratory MedicineAdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.drug_classPlaceboNitric Oxidelaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawBronchodilatorWheezeInternal medicineAdministration InhalationmedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsRespiratory systemAdverse effectAgedAged 80 and overInhalationbusiness.industryBeclomethasoneMiddle Agedrespiratory systemRespiration Disordersrespiratory tract diseasesTreatment Outcome030228 respiratory systemExhalationExhaled nitric oxideFemaleHuman medicinemedicine.symptombusiness
researchProduct

Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.

2016

Attempts at identifying patients with an elevated risk of bleeding while on anticoagulation following acute venous thromboembolism (VTE) have largely been unsuccessful thus far. We sought to develop a clinical prediction score for bleeding during stable anticoagulation treatment after acute VTE.We performed a post hoc analysis of the pooled RE-COVER studies, two double-blind randomised “sister” trials evaluating dabigatran versus standard treatment in 5107 VTE patients.A score was derived from patients randomised to dabigatran using logistic regression analysis covering the complete follow-up period. The final model, named VTE-BLEED, included six variables and yielded a c-statistic of 0.72 …

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAdolescentPopulationDecision MakingHemorrhage030204 cardiovascular system & hematologySensitivity and SpecificitySeverity of Illness Indexlaw.inventionDabigatranCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawRisk FactorsSeverity of illnessPost-hoc analysisMedicineHumans030212 general & internal medicineeducationAgedAged 80 and overeducation.field_of_studyModels Statisticalbusiness.industryStandard treatmentWarfarinAnticoagulantsVenous ThromboembolismSurgeryDabigatranROC CurveData Interpretation StatisticalRegression AnalysisFemaleWarfarinbusinessAlgorithmsCohort studymedicine.drugThe European respiratory journal
researchProduct

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma.

2002

The ability of omalizumab, an anti-immnoglobulin-E agent, to maintain long-term disease control in patients with moderate-to-severe allergic asthma was investigated in a 24-week double-blind extension to a 28-week core trial. During the extension, 483 of the initial 546 patients were maintained on randomised treatment and the lowest sustainable dose of beclomethasone dipropionate (BDP) as established during the steroid-reduction phase of the core trial. The use of concomitant asthma medication was permitted and investigators were allowed to adjust the BDP dose or switch patients from BDP to other asthma medications if deemed necessary. More omalizumab-treated patients (33.5%) than placebo-t…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyAllergyTime FactorsAdolescentOmalizumabOmalizumabImmunoglobulin EPlaceboAntibodies Monoclonal HumanizedSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHypersensitivityHumansAnti-Asthmatic AgentsAdverse effectChildAsthmaAgedbiologyDose-Response Relationship Drugbusiness.industryBeclomethasoneAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaSurgeryAntibodies Anti-IdiotypicTreatment OutcomeConcomitantbiology.proteinFemalebusinessmedicine.drugFollow-Up StudiesThe European respiratory journal
researchProduct